Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration

Naoko Koike,1 Tsuyoshi Otsuji,1 Akiko Tsumura,1 Katsuaki Miki,1 Yukio Sakai,1 Tetsuya Nishimura,1 Kanji Takahashi21Department of Ophthalmology, Kansai Medical University Medical Center, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical University, Osaka, JapanPurpose: Intravitreal injection...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Koike N, Otsuji T, Tsumura A, Miki K, Sakai Y, Nishimura T, Takahashi K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	AMD aflibercept ranibizumab switchback anti-VEGF drugs Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/cb6785829da04d9ea486f77c560f98fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb6785829da04d9ea486f77c560f98fe
record_format	dspace
spelling	oai:doaj.org-article:cb6785829da04d9ea486f77c560f98fe2021-12-02T10:11:49ZResults of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration1177-5483https://doaj.org/article/cb6785829da04d9ea486f77c560f98fe2019-07-01T00:00:00Zhttps://www.dovepress.com/results-of-switchback-from-ranibizumab-to-aflibercept-in-patients-with-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Naoko Koike,1 Tsuyoshi Otsuji,1 Akiko Tsumura,1 Katsuaki Miki,1 Yukio Sakai,1 Tetsuya Nishimura,1 Kanji Takahashi21Department of Ophthalmology, Kansai Medical University Medical Center, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical University, Osaka, JapanPurpose: Intravitreal injection of anti-VEGF drugs has become standard therapy for patients with exudative age-related macular degeneration (AMD). However, some patients do not exhibit sufficient response to the drugs for suppression of choroidal neovascularization activity. We investigated the efficacy of switchback from ranibizumab to aflibercept in patients with AMD who could not achieve further benefit beyond initial therapy of aflibercept injection.Methods: Eleven eyes of eleven patients were included in this study. Two patients were nonresponders, and nine exhibited tachyphylaxis to aflibercept. All patients received three monthly injections of ranibizumab as an initial phase of switching and received aflibercept as a switchback drug. We investigated changes in injection interval, visual acuity, and central retinal thickness.Results: In four patients (36.4%), injection interval was extended. The interval was 6.73 weeks before switch and 9.27 weeks after switchback (P=0.96). LogMAR visual acuity was 0.22 before switch and 0.24 after switchback (P=0.62). Central retinal thickness was 306.8 μm before switch and 256.1 after switchback (P=0.13). In all patients who were nonresponders to aflibercept, injection interval could not be extended.Conclusion: A switchback from ranibizumab to aflibercept may be beneficial in some patients with AMD who exhibit tachyphylaxis to aflibercept.Keywords: AMD, aflibercept, ranibizumab, switchback, anti-VEGF drugs  Koike NOtsuji TTsumura AMiki KSakai YNishimura TTakahashi KDove Medical PressarticleAMDafliberceptranibizumabswitchbackanti-VEGF drugsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1247-1251 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	AMD aflibercept ranibizumab switchback anti-VEGF drugs Ophthalmology RE1-994
spellingShingle	AMD aflibercept ranibizumab switchback anti-VEGF drugs Ophthalmology RE1-994 Koike N Otsuji T Tsumura A Miki K Sakai Y Nishimura T Takahashi K Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
description	Naoko Koike,1 Tsuyoshi Otsuji,1 Akiko Tsumura,1 Katsuaki Miki,1 Yukio Sakai,1 Tetsuya Nishimura,1 Kanji Takahashi21Department of Ophthalmology, Kansai Medical University Medical Center, Osaka, Japan; 2Department of Ophthalmology, Kansai Medical University, Osaka, JapanPurpose: Intravitreal injection of anti-VEGF drugs has become standard therapy for patients with exudative age-related macular degeneration (AMD). However, some patients do not exhibit sufficient response to the drugs for suppression of choroidal neovascularization activity. We investigated the efficacy of switchback from ranibizumab to aflibercept in patients with AMD who could not achieve further benefit beyond initial therapy of aflibercept injection.Methods: Eleven eyes of eleven patients were included in this study. Two patients were nonresponders, and nine exhibited tachyphylaxis to aflibercept. All patients received three monthly injections of ranibizumab as an initial phase of switching and received aflibercept as a switchback drug. We investigated changes in injection interval, visual acuity, and central retinal thickness.Results: In four patients (36.4%), injection interval was extended. The interval was 6.73 weeks before switch and 9.27 weeks after switchback (P=0.96). LogMAR visual acuity was 0.22 before switch and 0.24 after switchback (P=0.62). Central retinal thickness was 306.8 μm before switch and 256.1 after switchback (P=0.13). In all patients who were nonresponders to aflibercept, injection interval could not be extended.Conclusion: A switchback from ranibizumab to aflibercept may be beneficial in some patients with AMD who exhibit tachyphylaxis to aflibercept.Keywords: AMD, aflibercept, ranibizumab, switchback, anti-VEGF drugs
format	article
author	Koike N Otsuji T Tsumura A Miki K Sakai Y Nishimura T Takahashi K
author_facet	Koike N Otsuji T Tsumura A Miki K Sakai Y Nishimura T Takahashi K
author_sort	Koike N
title	Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
title_short	Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
title_full	Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
title_fullStr	Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
title_full_unstemmed	Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
title_sort	results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/cb6785829da04d9ea486f77c560f98fe
work_keys_str_mv	AT koiken resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT otsujit resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT tsumuraa resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT mikik resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT sakaiy resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT nishimurat resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration AT takahashik resultsofswitchbackfromranibizumabtoafliberceptinpatientswithexudativeagerelatedmaculardegeneration
_version_	1718397532780888064

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration

Ejemplares similares